AstraZenecaUS
@AstraZenecaUS
Followers
81K
Following
2K
Media
3K
Statuses
9K
We're transforming the future of healthcare by unlocking the power of what science can do. Intended for US HCPs. For info visit https://t.co/1B0LbPwpeO
Wilmington, DE
Joined January 2009
Today, in collaboration with @DaiichiSankyoUS we announced the @US_FDA approval of our treatment for adults with previously treated locally advanced or metastatic EGFR-mutated non-small cell #lungcancer #NSCLC. Learn more: #AZUS
1
1
8
Today, with @DaiichiSankyoUS, we announced high-level results from our DESTINY-Breast11 Phase III trial for HER2-positive early #breastcancer in the neoadjuvant setting. Learn more about the data and its potential impact for patients: #AZUS
2
2
4
RT @arunamiller: Yesterday, we joined @AstraZenecaUS to celebrate a $300 million investment in their new cell therapy facility in Montgomer….
0
7
0
Millions of people in the U.S. have dyslipidemia. These patients are often left uncontrolled by statin-only treatments, which can lead to cardiovascular events. We’re developing therapies to shape the future of care. Learn more: #ACC25
0
1
3
We’re targeting the root causes of inflammation in chronic respiratory diseases such as asthma, COPD and chronic rhinosinusitis with nasal polyps to transform care and patient outcomes. Learn more about our latest trial results in CRSwNP: #AAAAI25
12
4
9
The impacts of cardiovascular, renal and metabolic (CVRM) diseases on people continue to grow but may go under-recognized. We’re determined to demonstrate the impact of these diseases. Learn more: #HeartMonth
0
1
1
Better understanding the risk factors for high blood pressure (hypertension) may help improve outcomes. A lesser-known driver is aldosterone dysregulation. Aldosterone is a hormone that helps regulate blood pressure. #HeartMonth
0
2
2
Today, alongside @DaiichiSankyoUS, we announced the @US_FDA approval of a new indication for our therapy, now available for certain patients with previously treated metastatic #breastcancer. Learn more: #AZUS
2
2
8
Today, in collaboration with @DaiichiSankyoUS, we announced the @US_FDA approval of our new treatment for adults with previously treated advanced HR-positive, HER2-negative #breastcancer. Learn more: #AZUS
1
2
3
In collaboration with @DaiichiSankyoUS, we announced the @US_FDA granted a Breakthrough Therapy Designation for our potential treatment for adults with previously treated advanced EGFR-mutated non-small cell #lungcancer #NSCLC. #AZUS
1
2
4
We’re working to create healthier, longer futures for people living with cardiovascular, renal and metabolic diseases such as hypertension (HTN). Learn more about the drivers of HTN and ways to improve outcomes: #AHA2024
1
2
9
For people living with chronic respiratory diseases such as asthma, everyday tasks can feel challenging. Learn more about ways we’re working to evolve our pipeline and improve care for these vulnerable patients: #ACAAI
3
0
7
We're working to deeply understand ways long-term care management can improve outcomes for patients with chronic kidney disease, heart failure and their comorbidities including hyperkalemia (HK). Learn more about effectively managing HK: #ASN2024
2
1
5
To improve outcomes for people living with chronic respiratory diseases, we’re constantly pushing the boundaries of science to evolve our robust portfolio. Learn more about ways we’re revolutionizing care: #CHEST2024
2
2
5
We’re pleased to announce with @DaiichiSankyoUS the @US_FDA has accepted for review a supplemental Biologics License Application and granted Priority Review for our potential treatment for eligible patients with metastatic #breastcancer with certain levels of #HER2 expression.
1
2
2
Today we announced positive high-level results from our NIAGARA Phase III trial for muscle-invasive #BladderCancer (#MIBC), representing the first #immunotherapy regimen before and after surgery to extend survival in bladder cancer. Read more:
2
4
7
Today, the @US_FDA approved our IO-based therapy as treatment for adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient (dMMR). Learn how this approval provides a new treatment option for patients here:
2
2
7
At #EHA2024, we presented the full results from the ECHO Phase III trial in people with previously untreated #MantleCellLymphoma (#MCL). Read more here: #BloodCancer
3
0
5
Through our partnership with @NFWFnews, we’re committed to restoring 100 km of riverside woodlands and planting more than 100K trees. Together, we can create a more sustainable future for people, society & the planet. We are #GenerationRestoration.
We know that supporting a healthy environment is critical to people and planet. On #WorldEnvironmentDay we reaffirm our commitment to protecting and restoring nature to build a healthier future. We are #GenerationRestoration. Discover more:
6
0
3